The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for cancer, AIDS, multiple sclerosis and other serious maladies far over the going rate.

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging margins.

With a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide range of health solutions in the United States. With offerings that span pharmacy benefit management,

As the director, he represents Snyders Pharmacy’s fourth generation. The 95-year-old chain spans the stateline from Oregon to Poplar Grove. As customers head to the pharmacy desk, Felker describes the changes coming to the pharmacy: no more drive-thru.

CVS Health's poor 2024 performance could be turning around in 2025 with a new CEO and potential rebound, despite challenges. Read my analysis of CVS stock here.

Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs,

The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive on the streets of New York. Luigi Mangione ended up receiving an outpouring of support on social media from Americans furious how the Minnesota-based company mistreated their loved ones.

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive.

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases, thousands — of percent, resulting in $7.3 billion in revenue above cost.

The Federal Trade Commission accused UnitedHealth's OptumRx, CVS Caremark, and Cigna's Express Scripts of pocketing over $7 billion in markups on generic specialty drugs over a 5-year period. The Big Three PBMs drastically marked up specialty generic drug prices at affiliated pharmacies,